Literature DB >> 26787430

Oxytocin receptor gene variation predicts subjective responses to MDMA.

Anya K Bershad1,2, Jessica J Weafer1, Matthew G Kirkpatrick3, Margaret C Wardle4, Melissa A Miller1, Harriet de Wit1.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") enhances desire to socialize and feelings of empathy, which are thought to be related to increased oxytocin levels. Thus, variation in the oxytocin receptor gene (OXTR) may influence responses to the drug. Here, we examined the influence of a single OXTR nucleotide polymorphism (SNP) on responses to MDMA in humans. Based on findings that carriers of the A allele at rs53576 exhibit reduced sensitivity to oxytocin-induced social behavior, we hypothesized that these individuals would show reduced subjective responses to MDMA, including sociability. In this three-session, double blind, within-subjects study, healthy volunteers with past MDMA experience (N = 68) received a MDMA (0, 0.75 mg/kg, and 1.5 mg/kg) and provided self-report ratings of sociability, anxiety, and drug effects. These responses were examined in relation to rs53576. MDMA (1.5 mg/kg) did not increase sociability in individuals with the A/A genotype as it did in G allele carriers. The genotypic groups did not differ in responses at the lower MDMA dose, or in cardiovascular or other subjective responses. These findings are consistent with the idea that MDMA-induced sociability is mediated by oxytocin, and that variation in the oxytocin receptor gene may influence responses to the drug.

Entities:  

Keywords:  MDMA; OXTR; oxytocin; social behavior

Mesh:

Substances:

Year:  2016        PMID: 26787430      PMCID: PMC4988944          DOI: 10.1080/17470919.2016.1143026

Source DB:  PubMed          Journal:  Soc Neurosci        ISSN: 1747-0919            Impact factor:   2.083


  41 in total

1.  Culture, distress, and oxytocin receptor polymorphism (OXTR) interact to influence emotional support seeking.

Authors:  Heejung S Kim; David K Sherman; Joni Y Sasaki; Jun Xu; Thai Q Chu; Chorong Ryu; Eunkook M Suh; Kelsey Graham; Shelley E Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-19       Impact factor: 11.205

2.  'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content.

Authors:  Margaret C Wardle; Matthew G Kirkpatrick; Harriet de Wit
Journal:  Soc Cogn Affect Neurosci       Date:  2014-03-27       Impact factor: 3.436

3.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

4.  Common oxytocin receptor gene (OXTR) polymorphism and social support interact to reduce stress in humans.

Authors:  Frances S Chen; Robert Kumsta; Bernadette von Dawans; Mikhail Monakhov; Richard P Ebstein; Markus Heinrichs
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

5.  Thin-slicing study of the oxytocin receptor (OXTR) gene and the evaluation and expression of the prosocial disposition.

Authors:  Aleksandr Kogan; Laura R Saslow; Emily A Impett; Christopher Oveis; Dacher Keltner; Sarina Rodrigues Saturn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

6.  A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").

Authors:  M R Thompson; P D Callaghan; G E Hunt; J L Cornish; I S McGregor
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

7.  Can drugs be used to enhance the psychotherapeutic process?

Authors:  L Grinspoon; J B Bakalar
Journal:  Am J Psychother       Date:  1986-07

8.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

9.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Authors:  Dawn D Han; Howard H Gu
Journal:  BMC Pharmacol       Date:  2006-03-03

10.  Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach.

Authors:  F S Chen; R Kumsta; F Dvorak; G Domes; O S Yim; R P Ebstein; M Heinrichs
Journal:  Transl Psychiatry       Date:  2015-10-27       Impact factor: 6.222

View more
  16 in total

Review 1.  Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.

Authors:  Jonathan DePierro; Lauren Lepow; Adriana Feder; Rachel Yehuda
Journal:  Biol Psychiatry       Date:  2019-07-24       Impact factor: 13.382

2.  Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Matthew B Young; Seth D Norrholm; Lara M Khoury; Tanja Jovanovic; Sheila A M Rauch; Collin M Reiff; Boadie W Dunlop; Barbara O Rothbaum; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-07-24       Impact factor: 4.530

Review 3.  Pharmacological challenge studies with acute psychosocial stress.

Authors:  Kathryne Van Hedger; Anya K Bershad; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2017-08-22       Impact factor: 4.905

Review 4.  Progress and promise for the MDMA drug development program.

Authors:  Allison A Feduccia; Julie Holland; Michael C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2017-11-20       Impact factor: 4.530

5.  Effects of MDMA on attention to positive social cues and pleasantness of affective touch.

Authors:  Anya K Bershad; Leah M Mayo; Kathryne Van Hedger; Francis McGlone; Susannah C Walker; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2019-04-30       Impact factor: 7.853

6.  Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin.

Authors:  Sean B Dolan; Meredith S Berry; Patrick S Johnson; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2019-09-02       Impact factor: 4.153

7.  Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies.

Authors:  Erich Studerus; Patrick Vizeli; Samuel Harder; Laura Ley; Matthias E Liechti
Journal:  J Psychopharmacol       Date:  2021-03-30       Impact factor: 4.153

8.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

9.  Specification of Change Mechanisms in Pregnant Smokers for Malleable Target Identification: A Novel Approach to a Tenacious Public Health Problem.

Authors:  Suena H Massey; Jean Decety; Katherine L Wisner; Lauren S Wakschlag
Journal:  Front Public Health       Date:  2017-09-19

Review 10.  The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Authors:  Anya K Bershad; Melissa A Miller; Matthew J Baggott; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2016-08-25       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.